Drug Profile
Utomilumab - Pfizer
Alternative Names: PF-05082566; PF-2566; PF-5082566Latest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Immatics US; Kite Pharma; Kyowa Kirin; M. D. Anderson Cancer Center; Pfizer
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Oropharyngeal cancer
- Phase I/II Diffuse large B cell lymphoma; Solid tumours; Squamous cell cancer
- Phase I Follicular lymphoma; Ovarian cancer
- No development reported B-cell lymphoma; Colorectal cancer; Non-Hodgkin's lymphoma
Most Recent Events
- 20 Dec 2023 M.D. Anderson Cancer Center and National Cancer Institute completes a phase-I trial in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03318900)
- 05 Dec 2023 Eefficacy and adverse event data from a phase II AVIATOR trial in Breast cancer presented at 46th Annual San Antonio Breast Cancer Symposium 2023 (SABCS-2023)
- 31 May 2023 Utomilumab is still in phase) trials for (indication) in (Country)